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Abstract
Background: Continuous positive airway pressure (CPAP) in asthma patients with
concomitant obstructive sleep apnea syndrome (OSAS) seems to have a favorable
impact on asthma, but data are inconsistent due to methodological limitations of
previous studies.
Methods: Prospective, multicenter study. We examined asthma outcomes after
6 months of CPAP in 99 adult asthma patients (mean age 57 years) with OSAS
(respiratory disturbance index ≥20). Asthma control and quality of life were
assessed with the Asthma Control Questionnaire (ACQ) and the Mini Asthma
Quality of Life Questionnaire (MiniAQLQ), respectively. Data were analyzed by
intention-to-treat basis.
Results: The mean  SD score of the ACQ decreased from 1.39  0.91 at base-
line to 1.0  0.78 at 6 months (P = 0.003), the percentage of patients with uncon-
trolled asthma from 41.4% to 17.2% (P = 0.006), and the percentage of patients
with asthma attacks in the 6 months before and after treatment from 35.4% to
17.2% (P = 0.015). The score of the mAQLQ increased from 5.12  1.38 to
5.63  1.17 (P = 0.009). There were also significant improvements in symptoms
of gastroesophageal reflux and rhinitis, bronchial reversibility, and exhaled nitric
oxide values (all P < 0.05). No significant changes were observed in drug therapy
for asthma or their comorbidities nor in the patients’ weight.
Conclusions: Asthma control (both actual and future risk), quality of life, and
lung function improved after starting continuous positive airway pressure in asth-
matics with moderate to severe obstructive sleep apnea syndrome.
The Global Burden of Disease Study estimates that there are
334 million asthmatics worldwide, and the global prevalence
of obstructive sleep apnea syndrome (OSAS) exceeds 100 mil-
lion patients (1, 2). In the developed world, between 5% and
10% of the adult population suffer from asthma (3). Depend-
ing on the criteria used for diagnosis, OSAS affects 2-4% of
men and 1-2% of women in the United States (4), with an
estimated prevalence of 3-6% in the general Spanish popula-
tion (5). Being so prevalent, it is inevitable that a significant
percentage of patients suffer from both diseases
simultaneously. However, the relationship between asthma
and OSAS appears to be more complex than a casual associ-
ation. They share common risk factors and pathophysiologi-
cal mechanisms and are also detrimental to each other (6).
OSAS is an important risk factor for uncontrolled asthma
and for frequent exacerbations (7–11). In a prospective study
of 22 patients with difficult-to-control asthma, a night
polysomnography showed that all but one patient had OSAS
(95.5% prevalence) (7). Also, it has been shown that the
prevalence of OSAS increased progressively according to
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severity of asthma (from 58% in moderate asthma to 88% in
severe asthma) (9). In children with poorly controlled asthma
and frequent asthmatic exacerbations, the prevalence of
OSAS was markedly increased (63%) (10). Current asthma
clinical practice guidelines already include OSAS as a possi-
ble comorbidity affecting asthma management, and recom-
mend to investigate the presence of OSAS in the cases of
severe or uncontrolled asthma (12, 13).
In patients with OSAS and concomitant asthma, application
of continuous positive airway pressure (CPAP) has been
reported to provide benefits for asthma, although, in general,
these studies included a small number of subjects, lacked of a
control arm, were retrospective, had relatively short follow-up
times, and used heterogeneous criteria for the assessment of
outcomes, which limit the consistency of their conclusions (14–
18). In a recent survey among 1586 patients with OSAS of
which 12.4% were asthmatics, long-term treatment with CPAP
(mean of 5.7  4.7 years) was effective in reducing asthma
symptoms and improving asthma control in 152 patients (19).
To overcome some limitations of previous studies, we
designed a prospective, multicenter study with a large num-
ber of asthma patients with OSAS, the objective of which
was to examine the mid-term effect of CPAP on clinical and
functional asthma outcomes, using objective diagnostic tests
and validated questionnaires.
Methods
Study design
Between September 2011 and October 2014, a prospective
multicentre study was carried out in 15 acute-care hospitals
throughout Spain. The primary objective of the study was to
assess the clinical and functional course of asthma in the mid-
term (3 and 6 months) after starting treatment with CPAP in
patients with moderate–severe OSAS, including variables of
asthma control and health-related quality of life. As a sec-
ondary objective, possible differences in the clinical course of
asthma according to severity of both asthma and OSAS were
investigated. The study was conducted in accordance with the
Declaration of Helsinki (6th World Medical Assembly 2013)
and was approved by the Clinical Research Ethics Committee
of the Balearic Islands (approval number IB 1616/11 PI) and
registered at https://www.clinicaltrials.gov/ (NCT01374932).
Written informed consent was obtained from all participants.
Personal identification data were anonymized.
Participants
Patients previously diagnosed with asthma were consecutively
enrolled from the outpatient clinics of the Pneumology Ser-
vices involved in the study. Eligibility included men and
women aged between 18 and 70 with moderate to severe
OSAS (respiratory disturbance index ≥ 20). The diagnosis of
asthma and the classification of disease severity were estab-
lished according to the Global Initiative for Asthma (GINA)
criteria (20). Patients were excluded in the presence of a sev-
ere, decompensated comorbid disease or when their treatment
(ß-blockers, hypnotics, etc.) may interfere in the course of
asthma and/or OSAS; other pulmonary diseases different
from asthma with airflow limitation; cognitive impairment
that could limit the comprehension or collaboration of the
subject in the study; or a level of severity that, upon the
investigator’s judgment, prevented to apply the diagnostic
and therapeutic protocol of the study. Patients with an
asthma exacerbation episode between diagnosis of OSAS and
the beginning of unattended domiciliary CPAP therapy were
not eligible.
All subjects were na€ıve to CPAP. The CPAP equipments
had hour meter recording systems, so that machine-on time
hours could be checked at each clinical visit. During the first
3 months of study, changes in the pharmacological treatment
for asthma were not allowed, except during exacerbation epi-
sodes when doses of inhaled bronchodilator treatment could
be increased and oral glucocorticoids could be administered.
All patients on CPAP treatment, independently on the com-
pliance to CPAP therapy, remained in the study cohort.
Assessments and study procedures
A preestablished questionnaire was used to complete demo-
graphic variables; history and characteristics of asthma,
including severity (categorized as intermittent, mild persis-
tent, moderate persistent, and severe persistent), duration of
asthma, pharmacological treatment, exacerbations, respira-
tory function tests, sensitization to common aeroallergens
and comorbidities, including rhinitis, smoking status, obesity
(defined as body mass index [BMI] ≥ 30 kg/m2), and com-
mon subjective symptoms of gastroesophageal reflux disease
(GERD) (heartburn and/or regurgitation) reported by the
patients. Objective complementary examinations for the diag-
nosis of GERD at follow-up were not performed. Spanish-
validated versions of the Epworth Sleepiness Scale (ESS)
(21), the Asthma Control Questionnaire (ACQ) (22), and the
Mini Asthma Quality of Life Questionnaire (MiniAQLQ)
(23) were used to assess daytime sleepiness, asthma control,
and asthma-related quality of life, respectively.
Pulmonary function tests (spirometry and fractional
exhaled nitric oxide [FeNO]) were performed according to
recommendations of the Spanish Society of Pneumology and
Thoracic Surgery (SEPAR) (24, 25). Positive response to
bronchodilator testing was considered if forced expiratory
volume in one second (FEV1) increased ≥12% and 200 mL
as compared to baseline. Asthma exacerbations were defined
as an increase in symptoms (dyspnea, cough, wheezing, chest
tightness) needing unscheduled medical care of any type and/
or a change in medication (including the prescription of sys-
temic glucocorticoids). Well-controlled asthma was defined as
an ACQ score ≤ 0.75 and not well-controlled asthma as an
ACQ score ≥ 1.5 (26). The severity of rhinitis was graded
according to ARIA guidelines (27).
The diagnosis of OSAS was made by conventional full
polysomnography (30% of cases) or cardiorespiratory polyg-
raphy (70%) that included, at least, the following parameters:
oronasal flow (thermistor and nasal cannula), thoracoabdom-
inal movements, and pulse oximetry. Sleep studies were
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performed during a phase of at least 1 month of clinical sta-
bility of asthma. The different respiratory and electroen-
cephalographic events included in the calculation of the
respiratory disturbance index (RDI) were defined according
to guidelines of the Sleep Group of the SEPAR (28) and the
American Sleep Disorders Association (29). The intensity of
OSAS was classified into two levels based on RDI (≤30, and
>30 events/h). For each patient, titration of CPAP pressure
was performed by conventional polysomnography (28) or
using auto-CPAP equipment using a validated protocol (30).
Once patients were adapted to CPAP therapy, conventional
polysomnographies or nocturnal cardiorespiratory polygra-
phy with their CPAP machines was performed to assess effi-
cacy. It was considered that patients followed adequately
treatment with CPAP when the mean use of therapy was
equal or higher than 4 h/night.
Statistical analysis
In order to detect minimal clinically relevant differences (0.5
points) in the ACQ and MiniAQLQ, for an a risk of 0.05
and a ß risk of 0.20, and assuming up to 40% losses at fol-
low-up, a minimum of 90 patients were needed. Data were
analyzed on an intention-to-treat (ITT) basis, including all 99
patients in whom titration of CPAP was performed. There-
fore, in calculating proportions during the monitoring period,
the value of the denominator was kept in the initial 99 cases.
Categorical variables are expressed as frequencies and per-
centages, and quantitative variables as mean and SD. Pro-
portions were compared with the chi-square (v2) test or the
Fisher’s exact test, and quantitative variables with the Stu-
dent’s t-test or the Mann–Whitney U-test, according to the
normal or not normal distribution of data. The Student’s
t-test for paired data or the Wilcoxon rank-sum test was used
for the comparison of repeated measures. A logistic regres-
sion analysis was performed to assess the possible influence
of changes in comorbid diseases (rhinitis, GERD, obesity)
and the patient’s clinical condition (daytime sleepiness) on
the course of asthma. Two regression models were fitted. In
one model, a clinically relevant improvement in the control
of asthma (decrease ≥ 0.5 points in the ACQ) was the depen-
dent variable, with sex, decrease in BMI, reduction in the
percentage of patients with rhinitis, and symptoms of GERD
(heartburn and/or regurgitation) as binary independent vari-
ables (yes/no) and age as discrete independent variable. In
the second model, a relevant increase in the score of the Min-
iAQLQ was the dependent variable, with age, sex, and
decrease in BMI, reduction in the percentage of patients with
rhinitis and GERD, and decrease in the score of the EES
questionnaire as the independent variables. Statistical analy-
sis was performed with the SPSS version 15.0.1 (Statistical
Package for Social Sciences, SPSS, Inc., Chicago, IL, USA).
Statistical significance was set at P < 0.05.
Results
The flowchart of study participants is shown in Fig. 1. Of
the 121 patients who met the inclusion criteria, 22 were not
included for the following reasons: refusal of CPAP therapy
(n = 3), presence of an asthma exacerbation immediately
before starting CPAP (n = 2), and CPAP titration not carried
out for different reasons (n = 17). Therefore, the intention-
to-treat study population included 99 patients (60 men and
39 women) with a mean age of 57.1  11.4 years.
As shown in Table 1, significant differences between partic-
ipants and nonparticipants were not observed, except for a
higher cardiovascular comorbidity among participants. At
follow-up, four patients failed to tolerate CPAP and discon-
tinued the study and 13 patients were lost for different
causes.
Baseline characteristics of the study population are shown
in Table 2. Patients were all receiving asthma medications for
at least 6 months (92% inhaled glucocorticoids). Patients
with moderate–severe asthma as compared to those with
intermittent–mild asthma had significantly lower values of
FEV1, higher frequency of positive bronchodilation test,
more intense pharmacological treatment, and poorer asthma
control and quality of life. Percentages of obese patients and
patients with GERD symptoms were also significantly higher.
However, differences in sleep parameters, daytime somno-
lence, and mean CPAP pressure were not observed. Seventy-
five patients (75.8%) showed a RDI > 30 and 24
(24.2%) ≤30.
Clinical and functional characteristics of patients
At the end of the six-month follow-up period, no significant
changes were observed in the mean values of FEV1, in the
mean weight of patients, or in the percentage of current
smokers. Also, there were no significant differences in the
pharmacological treatment for asthma, rhinitis, or GERD
(Table 3) between 3 and 6 months and between baseline and
6 months. However, the percentage of patients with mild
rhinitis, heartburn, and regurgitation decreased significantly,
as well as the mean score of the ESS (Table 3). Finally, the
mean fractional exhaled nitric oxide (FeNO) and the percent-
age of patients with positive bronchodilation test showed a
significant decrease (Table 3).
Current asthma control and future risk of asthma-related
events
The mean score of the ACQ at baseline of 1.39  0.91
decreased to 1.11  0.86 (P = 0.032) and 1.0  0.78
(P = 0.003) at 3 and 6 months, respectively. Improvement in
asthma control was also observed in all categories of both
asthma and OSAS severity (Table 3), but only reached statis-
tical significance in patients with moderate–severe asthma or
severe OSAS (RDI > 30). In addition, the percentage of
patients with well-controlled asthma increased from 28% to
38% at 6 months and the percentage of patients with not
well-controlled asthma decreased from 41% to 17%. All
these differences were statistically significant (Fig. 2).
Considering only clinically relevant ACQ changes (≥0.5
points), asthma control improved in 34.7% (34 of 98) of
patients and worsened in only one patient.
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According to the level of asthma control at baseline,
improvement was recorded in 58.5% (24 of 41) of patients
with not well-controlled asthma as compared to 7.1% (2 of
28) of those with well-controlled asthma (P < 0.001). In the
multivariate analysis, decrease in body mass index (BMI)
(odds ratio [OR] 0.76, 95% confidence interval [CI] 0.30-
1.93), clinical improvement of rhinitis (OR 1.37, 95% CI
0.42-4.48), or GERD symptoms (OR 0.65, 95% CI 0.21-1.96)
were not associated with better asthma control. On the other
hand, 39 patients had a humidifier in CPAP at 3 months and
37 at 6 months, but differences in asthma control between
those with CPAP with a humidifier compared with those with
CPAP without a humidifier were not observed.
The percentage of patients with at least one asthma exacer-
bation decreased from 24.2% (n = 24) to 8.2% (n = 8)
(P = 0.004) when the three-month pretreatment and post-
treatment periods were compared, and from 35.4% (n = 35)
to 17.2% (n = 17) (P = 0.015) when comparison was
extended to the six-month pretreatment and post-treatment
periods. During the first 3 months of follow-up, five patients
with asthma exacerbation required treatment with oral gluco-
corticoids. No hospital admissions for asthma exacerbations
were recorded during the study.
Quality of life
Asthma-related quality of life improved throughout the
study. The mean score of the MiniAQLQ at baseline of
5.12  1.38 increased to 5.53  1.23 (P = 0.032) at 3 months
and to 5.63  1.17 (P = 0.009) at 6 months. Improvement in
quality of life was recorded in all categories of both asthma
and OSAS severity (Table 3). However, the differences only
reached statistical significance in the groups of moderate–
severe asthma or severe OSAS (RDI > 30).
Considering only clinically relevant MiniAQLQ changes
(≥0.5 points), quality of life improved in 38.4% (38 of 99) of
patients and worsened in 7.1% (7 of 99). Improvement in
quality of life was recorded in 53.7% (22 of 41) of patients
with not well-controlled asthma at baseline as compared to
14.3% (4 of 28) of those with well-controlled asthma. By
contrast, decreases of ≥0.5 in the MiniAQLQ were more
common among patients with well-controlled asthma (10.7%
[4 of 28]) than among those with not well-controlled asthma
(4.9% [2 of 41]).
In the multivariate analysis, female sex was an independent
factor associated with an improvement in quality of life (OR
3.01, 95% CI 1.08-8.41, P = 0.035). However, a decrease in
Figure 1 Flowchart of the study population. CPAP, continuous positive airway pressure; OSAS, obstructive sleep apnea syndrome; RDI, res-
piratory disturbance index.
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BMI (OR 1.49, 95% CI 0.56-3.98), clinical improvement of
rhinitis (OR 1.80, 95% CI 0.52-6.20) or GERD symptoms
(OR 1.04, 95% CI 0.34-3.22), or reduction in daytime sleepi-
ness (OR 3.72, 95% CI 0.67-20.65) was not associated with
relevant improvements in quality of life.
Asthma control and quality of life according to compliance
with CPAP
Asthma control and quality of life at 6 months were higher
among patients compliant with CPAP (≥4 h/night) as com-
pared to noncompliant subjects. Differences between baseline
and final scores were only significant (P < 0.001) in the com-
pliance group (Fig. 3).
Discussion
This study shows that after 6 months of treatment with
CPAP, there was a decrease in the percentage of patients
with positive bronchodilation test, a decrease in FeNO, and
a reduction in the score of the ACQ. All these changes
occurred without a significant modification of asthma drug
therapy.
The beneficial effect of CPAP was associated with a better
control of asthma, which was statistically significant and clin-
ically relevant. The percentage of patients with not well-
controlled asthma decreased from 41% at baseline to 27% at
3 months and 17% at 6 months. At the same time, a reduc-
tion in the number of asthma exacerbations was observed
(from 35.4% to 17.2% during the six-month pretreatment
and post-treatment periods). This favorable effect was also
extended to a significant improvement in asthma-related
quality of life, which was especially noticeable in the subset
of patients with more severe diseases (OSAS and asthma) or
poorly controlled asthma at baseline.
We believe our study adds significant evidence to previous
authors, who reported a favorable impact of CPAP therapy
in patients with OSAS. The first studies, carried out in the
1980s, consisted in series of 9-10 patients followed sometimes
for only 2 weeks (14, 15). More recently, other groups have
confirmed the positive effects of treating OSAS (in adults
using CPAP and in children undergoing adenoidectomy and
tonsillectomy) in the clinical course of asthma (10, 17–19). In
contrast, the effects of CPAP therapy on pulmonary function
of asthmatic patients with OSAS are less common and lim-
ited to small improvements in blood gases (16) or small
increases (around 10%) in the peak expiratory flow rate (14).
In relation to pulmonary function, we found a favorable
evolution in the degree of bronchial reversibility and a dis-
crete, but significant, decrease in the mean value of FeNO.
Other authors have evaluated the relationship between FeNO
and OSAS, and the effects of CPAP therapy on FeNO, with
relatively contradictory results (31–33). In nonasthmatic
patients with OSAS, different studies have shown an increase
in FeNO attributed to tissue inflammation of the upper air-
way directly related to the intensity of OSAS. After 1 to
3 months of CPAP therapy, FeNO levels usually normalized
(31, 32). Other studies of shorter treatment periods did not
found any improvement (33). The relationship between
OSAS, obesity, local airways inflammation, and bronchial
hyperresponsiveness (BHR) has also been extensively studied,
as well as the response after CPAP therapy (33–38). In
patients with asthma, a reduction in BHR has been reported
in the majority of studies (34, 35). By contrast, in nonasth-
matic patients with OSAS, BHR frequently increases (33,
36), although not always (37). In the present study, in which
patients suffer from asthma and OSAS concurrently, it is
possible that changes observed in FeNO values and bron-
chodilation test may represent a balance of the global effect
of CPAP on both conditions.
Another interesting finding was the improvement in two
diseases usually associated with asthma, rhinitis, and GERD,
in the absence of relevant changes in their pharmacologic
treatment or in the patients’ weight. In this respect, immedi-
ate improvements of gastroesophageal reflux, after only one
night of CPAP therapy, have been reported. These
Table 1 Comparison of characteristics of participants and nonparticipants
Variables Participants (n = 99) Nonparticipants (n = 22) P value
Age, years, mean  SD 57.1  11.4 52.8  16.7 0.259
Men/women, % 61/39 54/46 0.600
Body mass index, kg/m2, mean  SD 34.5  6.0 35.8  10.6 0.606
Smoking status, %
Current smoker 8 14 0.360
Ex-smoker 39 50
Never smoker 53 36
Cardiovascular comorbidity, % 44 18 0.023
Severity of asthma, %
Intermittent 11 14 0.915
Mild persistent 17 18
Moderate persistent 48 50
Severe persistent 24 18
Respiratory disturbance index (RDI), mean  SD 46.3  20.8 42.7  29.7 0.503
Epworth Sleepiness Scale, mean  SD 12.8  4.9 11.7  5.9 0.370
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improvements in GERD have been confirmed by esophageal
pH monitoring and esophageal manometry (15, 39).
The mechanisms by which treatment with CPAP may
improve symptoms and asthma control are multiple. OSAS is
associated with a systemic and local inflammation of the air-
ways, as well as pulmonary vascular changes and release of
endothelial factors (such as vascular endothelial growth fac-
tor) with proinflammatory effects (40). The use of CPAP
reduces inflammation and its mediators (31). Improvement of
gastroesophageal reflux may also be accompanied by a reduc-
tion in nocturnal asthma symptoms (15). Additionally, reduc-
tion in bronchial hyperresponsiveness produced by CPAP
Table 2 Demographic and clinical characteristics of patients according to asthma severity
Total (n = 99)
Intermittent–Mild
persistent asthma
(n = 28)
Moderate–Severe
persistent asthma
(n = 71) P value
Age, years, mean  SD 57.1  11.4 54.9  14.2 58.0  10.0 0.296
Men/women, % 61/39 64/36 59/41 0.638
Body weight, kg, mean  SD 94.2  15.6 89.3  14.4 96.1  15.7 0.049
Body mass index, kg/m2, mean  SD 34.5  6.0 32.2  5.5 35.5  5.9 0.013
Body mass index ≥ 30, % 76 57 83 0.007
Smoking status, %
Current smoker 8 4 10 0.706
Ex-smoker 39 43 38
Never smoker 53 53 52
Cardiovascular comorbidity, % 44 39 47 0.517
Rhinitis, % 54 57 52 0.651
Moderate–severe rhinitis, % 34 31 35 0.784
Nasal polyposis, % 18 14 20 0.528
Gastroesophageal reflux symptoms disease, %
Heartburn 31 21 35 0.197
Regurgitation 19 4 25 0.016
Regular medical control of asthma, % 74 68 76 0.404
FEV1, % predicted, mean  SD 83.6  17.6 90.9  14.4 80.8  18.1 0.010
Positive bronchodilation test, % 36 21 42 0.052
FeNO, ppb, mean  SD 29.9  18.7 26.0  21.1 31.0  18.2 0.484
Sensitization to aeroallergens, % 59 57 60 0.739
Asthma Control Questionnaire (ACQ), score, mean  SD 1.39  0.91 0.88  0.54 1.58  0.95 <0.001
Control of asthma, %
ACQ ≤ 0.75 28.6 48.1 21.1 0.002
ACQ 0.76-1.49 29.6 37.0 26.8
ACQ ≥ 1.5 41.8 14.9 52.1
Exacerbations previous 6 months, % 35 39 34 0.547
Pharmacological treatment, %
Short-acting ß2 adrenergic agonists 86 82 87 0.530
Long-acting ß2 adrenergic agonists 83 61 92 0.001
Inhaled glucocorticoids 92 75 99 0.001
Oral glucocorticoids 0 0 0 1.0
Leukotriene antagonists 35 32 37 0.675
Antacids 21 21 21 0.974
Nasal glucocorticoids 18 11 21 0.226
Equivalent doses of budesonide, mcg/day, mean  SD 926  716 517  651 1048  693 <0.001
MiniAQLQ score, mean  SD 5.12  1.38 5.77  0.93 4.87  1.45 0.001
Epworth Sleepiness Scale, mean  SD 12.8  4.9 13.6  5.5 12.5  4.7 0.310
Epworth Sleepiness Scale >11, % 60 61 59 0.887
Respiratory disturbance index, mean  SD 46.3  20.8 50.0  20.4 44.8  20.9 0.266
CT90, mean  SD 22.2  24.7 26.1  23.9 20.7  25.1 0.135
CPAP pressure, cm H2O, mean  SD 9.0  1.6 8.6  1.5 9.1  1.6 0.266
Respiratory disturbance index residual, mean  SD 5.7  5.6 5.2  5.6 5.9  5.7 0.691
CT90 residual, mean  SD 5.5  11.2 3.6  8.0 6.2  12.3 0.905
FEV1, forced expiratory volume in one second; FeNO, exhaled nitric oxide fraction; MiniAQLQ, Mini Asthma Quality of Life Questionnaire;
CT90, percentage of time with arterial oxygen saturation <90%; CPAP, continuous positive airway pressure.
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(34) can be also associated with a clinical improvement of
asthma.
An interesting finding was that female gender was an inde-
pendent predictive factor for improvement in quality of life.
Women as compared with men showed a lower proportion of
severe persistent asthma (12.8% vs 54.6%, P = 0.002) and
higher proportion of moderate persistent asthma (61.5% vs
38.3%, P = 0.024), lower mean baseline score of the Min-
iAQLQ (4.73  1.64 vs 5.34  1.12, P = 0.049), with a signifi-
cantly higher increase in mean score of the MiniAQLQ at
follow-up (0.84  1.09 vs 0.35  0.96, P = 0.040). Therefore,
it is possible that a higher percentage of women with less severe
asthma than men and lower baseline quality of life score may
allow theoretically a greater margin for improvement.
Smokers and ex-smoker asthma patients were included in
the study, so we cannot rule out the presence of ACOS (41)
in some of them. Nevertheless, the impact of this circum-
stance in our results would be very small. Of the 99 patients
included in the study, only 26 had persistent airflow limita-
tion (never smokers: 13; ex-smokers: 12; and current smok-
ers: 1). Therefore, the theoretical maximal percentage of
patients with ACOS would be 13.1%, which should be fur-
ther reduced after the exclusion of patients with a cumulative
dose of tobacco exposure <10 pack years.
Table 3 Changes in clinical and functional variables, asthma control, and quality of life after starting treatment with continuous positive
airway pressure
Baseline
Final six-month
follow-up P value
Clinical and functional characteristics
Body mass index (BMI), kg/m2, mean  SD 34.5  6.0 34.5  5.7 0.938
Current smokers, % 8 2 0.100
Mild rhinitis, % 35.4 22.2 0.041
Moderate–severe rhinitis, % 18.2 15.2 0.567
Heartburn 30.3 10.1 <0.001
Regurgitation 18.2 5.1 0.007
FEV1, % predicted, mean  SD 83.6  17.6 83.6  16.6 0.977
Positive bronchodilation test, % 36.4 12.1 <0.001
FeNO, ppb, mean  SD 29.9  18.7 22.0  12.5 0.041
Pharmacological treatment, %
Inhaled glucocorticoids, equivalent doses of budesonide
mcg/day, mean  SD 926  716 946  765 0.988
≤400 mcg/day, % 39.6 37.3 0.826
401-800 mcg/day, % 24.2 28
>800 mcg/day, % 36.3 34.7
Leukotriene antagonists 35.4 32.3 0.652
Nasal glucocorticoids 18.2 20.2 0.718
Antihistamines 21.2 16.2 0.362
Antacids 21.2 19.2 0.723
Epworth Sleepiness Scale, mean  SD 12.8  4.9 6.9  4.1 <0.001
Epworth Sleepiness Scale >11, % 59.6 13.1 <0.001
Control of asthma
Asthma Control Questionnaire (ACQ) score, mean  SD 1.39  0.91 1.00  0.78 0.003
ACQ score according to asthma severity, mean  SD
Intermittent–mild persistent 0.88  0.54 0.71  0.45 0.226
Moderate–severe persistent 1.58  0.95 1.11  0.85 0.003
ACQ score according to OSAS severity, mean  SD
RDI ≤ 30 1.47  0.88 1.02  0.88 0.113
RDI > 30 1.36  0.92 0.99  0.76 0.012
Asthma-related quality of life
MiniAQLQ score, mean  SD 5.12  1.38 5.63  1.17 0.009
MiniAQLQ score according to asthma severity, mean  SD
Intermittent–mild persistent 5.77  0.93 6.04  0.85 0.303
Moderate–severe persistent 4.87  1.45 5.48  1.24 0.012
MiniAQLQ score according to OSAS severity, mean  SD
RDI ≤ 30 5.23  1.44 5.68  1.41 0.324
RDI > 30 5.08  1.37 5.62  1.11 0.013
FeNO, exhaled nitric oxide fraction; OSAS, obstructive sleep apnea syndrome; MiniAQLQ, Mini Asthma Quality of Life Questionnaire; RDI,
respiratory disturbance index.
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The present study has strengths and limitations. Strengths
include the prospective and multicentre design, the adequate
sample size, the six-month duration of CPAP treatment, and
the assessment of results using objective diagnostic tests and
validated questionnaires. The observational nature of the
study is one of its main limitations. In order to confirm
definitively that the favorable clinical course of asthma in
our patients was due to the use of CPAP, a randomized con-
trolled trial might be considered necessary. But the execution
of a randomized trial like that has considerable theoretical
and practical difficulties. First, in addition to including a
sham-CPAP arm, it would be also necessary to assess objec-
tively patients’ adherence to pharmacological treatment,
including inhaled therapy for asthma. With respect to sham-
CPAP, it is possible, moreover, that this procedure may not
be a suitable placebo in patients with asthma. Busk et al.
(34) studied the effect of CPAP in the short term (7–10 days)
on BHR in asthmatic patients with low risk of OSAS. In the
control group, with pressures of 0-2 cmH2O CPAP, the
increase in the provocative concentration of methacholine
causing a 20% fall in forced expiratory volume in 1 s (PC20)
was lower than in the group using CPAP therapeutic pres-
sures. However, although the mean variation in the PC20 did
not reach statistical significance, 55% of patients who
received sham-CPAP showed a decrease in the BHR. On the
other hand, in patients with OSAS, it has been observed a
significant difference after using sham-CPAP both in the
degree of daytime hypersomnia and in several polysomno-
graphic parameters: While hypersomnia improved (42), the
quality of the sleep became worse (decreased sleep efficiency,
increased time in stage 1 NREM sleep, and prolonged
latency to REM sleep) (43). Therefore, taking into account
the existing correlations between sleep quality, daytime
hypersomnia, quality of life, and asthma control (44, 45),
and the potential effect of sham-CPAP in BHR (34), it can-
not be excluded that subtherapeutic CPAP pressures, used as
a placebo in asthmatic patients with OSAS, may have rele-
vant effects on asthma outcomes that would distort the
results of a controlled study. Finally, there are ethical issues
regarding keeping patients with OSAS without active treat-
ment, in patients with two potentially severe diseases. All
these considerations were taken into account in the final deci-
sion regarding the design of our study. However, an overall
evaluation of all the results obtained is highly suggestive of a
probable beneficial effect per se of the use of CPAP, with a
progressive convergence in the improvement of the different
study variables: asthma control, asthma-related quality of
life, bronchial inflammation and response to bronchodilator
test, as well as clinical symptoms of rhinitis and GERD. All
of these findings occurred without significant changes in the
mean weight of patients and in the pharmacological treat-
ment for asthma or its comorbidities during the follow-up
period. A significant association between clinically relevant
changes in the evolution of asthma and improvement of
comorbidity of OSAS and/or asthma was not observed.
Finally, differences in ACQ and MiniAQLQ according to the
level of compliance with CPAP treatment, with significant
improvements only among good compliant patients, are also
remarkable.
Conclusions
In patients with asthma and concomitant moderate–severe
OSAS, we observed an improvement in current control of
Figure 2 Number of patients with well-controlled asthma (ACQ score ≤ 0.75) and not well-controlled asthma (ACQ score ≥ 1.5) after start-
ing continuous positive airway pressure. ACQ, Asthma Control Questionnaire. Expression of results and statistical analysis (v2) made by
intention-to-treat basis; *one patient did not complete the ACQ.
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asthma and quality of life, together with a reduction in
future risk, after starting CPAP therapy. This effect was
stronger in patients with more severe asthma or OSAS, in
those with uncontrolled asthma, and in patients compliant
with CPAP. These observations provide further arguments to
emphasize the need of screening and eventually treating
OSAS in patients with severe or poorly controlled asthma.
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